ADVA
4.11.2021 09:02:12 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that CSC – IT Center for Science, which operates the Finnish University and Research Network (FUNET), has set an industry record by transporting 800Gbit/s farther than ever before over a live network. Using the ADVA FSP 3000 TeraFlex™ CoreChannel™ , FUNET’s succeeded in transmitting data at 800Gbit/s on links exceeding 2,000km. The field trial shows how network operators can leverage new value in existing large-scale infrastructure and how FUNET can empower the Nordics’ academics and scientists to achieve even more. Harnessing 140GBd sub-carrier technology, ADVA’s new CoreChannel™ sled leverages 150GHz channel spacing, enabling TeraFlex™ to deliver the market’s longest reach for a single-channel 800Gbit/s solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005050/en/
“ADVA’s FSP 3000 TeraFlex™ CoreChannel™ at 800Gbit/s speed delivered impressive reach during our tests and was stable throughout the month-long test period when we ran it on our nationwide ADVA open line system . The new 800Gbit/s channel technology will give us more flexibility to choose optimum modulation per use case to improve spectral efficiency. And, more importantly, it maps efficiently to 400GbE client services,” said Jani Myyry, senior network specialist, CSC/FUNET. “This field trial demonstrates that our network can smoothly support future requirements and deliver even more to our users in the Finnish research and education community. It also will strengthen our confidence that the first multi-Terabit services we aim to deliver early next year together with other Nordic research and education networks can be implemented successfully.”
With the addition of the new CoreChannel™ sled , ADVA’s FSP 3000 TeraFlex™ is the industry’s most efficient high-capacity open optical terminal for all applications from metro to submarine links. Now trials in the ultra-long-haul FUNET transport system have proven its compatibility with deployed infrastructure and shown that it offers excellent performance in a live flexgrid network built with multi-degree ROADMs and RAMAN amplifiers. TeraFlex™ CoreChannel™ also delivers industry-leading SNR requirements, making it resilient to transmission impairments. Featuring multi-rate client support, the CoreChannel™ sled can also transport any mix of 400GbE, 100GbE and 10GbE services, protecting investment and providing complete flexibility.
“It’s fantastic to see our FSP 3000 TeraFlex™ with CoreChannel™ sled pass this major test with such flying colors. Even over the FUNET network’s longest distances, the solution surpassed expectations and showed how incredible speeds are now possible at the lowest possible cost per bit per kilometer,” commented Cornelius Fürst, director, product line management, ADVA. “One of the reasons our FSP 3000 TeraFlex™ CoreChannel™ is able to provide such great long-haul performance is that it carries data at 800Gbit/s using a 150GHz window. Not only does this help to reduce complexity and avoid stranded bandwidth, but it also makes the technology future-proof. 150GHz is the channel spacing that offers the best balance between fiber capacity and optical reach. That’s why it’s gaining traction across the industry and why our open FSP 3000 TeraFlex™ CoreChannel™ sled is ready for new innovation further down the line.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About CSC – IT Center for Science Ltd.
CSC – IT Center for Science is a Finnish center of expertise in information technology owned by the Finnish state and higher education institutions. We provide internationally high-quality ICT expert services for higher education institutions, research institutes, culture, public administration and enterprises. For more information, please visit www.csc.fi
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005050/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom